{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:10:44Z","timestamp":1791317444971,"version":"4.3.1"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T00:00:00Z","timestamp":1357776000000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The antiparasitic agent moxidectin is under development for the treatment of onchocerciasis. As the first\u2010in\u2010human study of moxidectin used a liquid formulation but other trials used tablets, a study was performed to determine the relative bioavailability of the 2 formulations and to gain more information about the pharmacokinetics of moxidectin. Fifty\u2010eight healthy male participants were randomized to receive open\u2010label moxidectin (10 mg) as a tablet (n = 29) or liquid (n = 29) formulation. The mean \u00b1 SD pharmacokinetic parameters observed following administration of the tablet were peak concentration (C<jats:sub>max<\/jats:sub>) 67.1 \u00b1 27.4 ng\/mL, time to peak concentration (t<jats:sub>max<\/jats:sub>) 3.2 \u00b1 1.4 hours, area under the concentration time curve (AUC) 4403 \u00b1 2360 ng\u00b7h\/mL, apparent volume of distribution 3635 \u00b1 1720 L, oral clearance 2.83 \u00b1 1.25 L\/h, and elimination half\u2010life 1032 \u00b1 502 hours. The C<jats:sub>max<\/jats:sub> and AUC observed following administration of the liquid formulation were 28.6% and 28.8% higher, respectively, and t<jats:sub>max<\/jats:sub> 0.9 hours shorter compared with tablets. No serious adverse events (AEs) were observed. The most commonly reported AEs were headache, infection, diarrhea, asthenia, myalgia, and dizziness during the inpatient phase and flu syndrome, headache, and infection during the 6\u2010month outpatient phase. There was no difference in reporting of these AEs between formulations.<\/jats:p>","DOI":"10.1177\/2160763x11432508","type":"journal-article","created":{"date-parts":[[2012,1,25]],"date-time":"2012-01-25T15:33:20Z","timestamp":1327505600000},"page":"32-37","source":"Crossref","is-referenced-by-count":38,"title":["Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin"],"prefix":"10.1002","volume":"1","author":[{"given":"Joan M.","family":"Korth\u2010Bradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Patat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Matschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fleckenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0001-706X(91)90015-C"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)12450-3"},{"key":"e_1_2_7_4_2","unstructured":"World Health Organization.Working to overcome the global impact of neglected tropical diseases: update to WHO report on neglected tropical diseases.2011.http:www.who.intneglected_diseases2010reportWHO_NTD_report_update_2011.pdf. Accessed October 16 2011."},{"key":"e_1_2_7_5_2","unstructured":"African Programme for Onchocerciasis Control.Final communiqu\u00e9 of the 11th session of the Joint Action Forum of APOC Paris France 69 December 2005. Ouagadougou (Burkina Faso). 2005.http:www.who.intapocaboutstructurejafjaf11_final_communique.pdf. Accessed November 8 2010."},{"key":"e_1_2_7_6_2","volume-title":"Onchocerciasis and Its Control: Report of a WHO Expert Committee on Onchocerciasis Control","author":"World Health Organization.","year":"1995"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030371"},{"key":"e_1_2_7_8_2","first-page":"495","article-title":"Socioeconomic consequences of blinding onchocerciasis in West Africa","volume":"73","author":"Evans T.G.","year":"1995","journal-title":"Bull World Health Organ"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2003.01192.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(99)00389-5"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70099-9"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1996.11813075"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/371707a0"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(02)00852-3"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/jf00038a028"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-004-9004-4"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003257456"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00120-6"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F2160763X11432508","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2160763X11432508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:02:27Z","timestamp":1698710547000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/2160763X11432508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1177\/2160763X11432508"],"URL":"https:\/\/doi.org\/10.1177\/2160763x11432508","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}